Pre-earnings options volume in Corcept Therapeutics (CORT) is normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move near 3.7%, or $2.71, after results are released. Median move over the past eight quarters is 5.2%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Positive Outlook for Corcept Therapeutics: Buy Rating Backed by Strong Financial Guidance and Pipeline Advancements
- Corcept Therapeutics (CORT) Q1 Earnings Cheat Sheet
- Corcept Therapeutics initiates trial of Phase 2 trial BELLA
- Corcept Therapeutics price target raised to $131 from $128 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today